The global monoclonal antibody therapeutics market is set to witness a growth rate of ~12% in the next 5 years. Rising prevalence of chronic and autoimmune diseases, advancements in the technologies related to drug engineering and development, increased funding and investments into research and development, approval of monoclonal antibody therapies, increased acceptance of personalized medicine, and expanding applications of mAB therapy in various medical fields, are some of the key factors driving the monoclonal antibody therapeutics market.
Monoclonal antibodies (mAbs) are antibodies produced by a clonal population of B cells and bind to a single target antigen. A therapeutic mAb is a homogenous collection of antibodies used to treat illnesses. mAbs are selected based on their affinity for a target antigen. The target can be a plasma protein, infectious organism, cell surface antigen, or IgG receptor, depending on the mechanism of treatment. mAbs are used in immunotherapies in different ways, like to stimulate the patient’s immune system, to modulate/inhibit a biochemical disease pathway to deliver a therapeutic radionuclide or drug to a target cell type. Therapeutic mAbs exhibit much higher specificity than small molecule drugs, which minimizes adverse side effects, especially when highly toxic drug substances must be delivered.
🔗 Want deeper insights? Download the sample report here:
https://meditechinsights.com/monoclonal-antibody-therapeutics-market/request-sample/
Increasing prevalence of chronic and autoimmune diseases to drive market growth
Severity and prevalence of chronic and autoimmune diseases are the key factors driving the market for mAB therapeutics. In 2023, 76.4% of adults over the age of 18 in the US were suffering from at least one chronic illness, this marks an increase from 72.3% reported in 2013. In addition, participants with multiple chronic conditions (two or more) also showed an increase from 47.3% to 51.4% during the same time period (Source: CDC). Furthermore, autoimmune diseases affect 5 to 10% of the population in industrialized countries (Source: Global Autoimmune Institute). The growing prevalence of such chronic and autoimmune diseases is driving the global need for mAbs or monoclonal antibodies which are precise and strongly effective directed therapies. The high specificity of mAbs helps in protecting healthy tissues from damage which greatly improves outcomes. mAbs are most suitable for the treatment of complex immune related disorders due to their ability to target disease related epitope markers, leading to increased mAbs market growth.
Advancements in the technologies related to drug engineering and development to propel market growth
Advancements in the drug engineering and therapy development technologies are propelling the growth of the monoclonal antibody therapeutics market. Modern advances, including recombinant DNA, high-throughput screening, and complex cell line development, have pushed therapies to the limits of efficacy, safety, and specificity of treatment with monoclonal antibodies. These approaches enable production of both humanized and completely human, as shielded, or bispecific antibodies as well as those with improved therapeutic indexes and less side effects. In addition, the efficacy of mAb of cancer and other diseases can be increased by antibody-drug conjugates (ADCs) combining mAbs specificity and potently active drugs. These improvements shorten the timescale taken to develop drugs and reduce production expenses, expanding the scope of treatable conditions and rendering the market bigger.
Competitive Landscape Analysis
The global monoclonal antibody therapeutics market is marked by the presence of established and emerging market players such as F. Hoffmann-La Roche Ltd; AbbVie Inc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb (BMS); Amgen Inc.; Novartis AG; Eli Lilly and Company; Sanofi; and AstraZeneca; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Get PDF Report for Competitive Analysis:
https://meditechinsights.com/monoclonal-antibody-therapeutics-market/request-sample/
Global Monoclonal Antibody Therapeutics Market Segmentation
This report by Medi-Tech Insights provides the size of the global monoclonal antibody therapeutics market at the regional- and country-level from 2023 to 2030. The report further segments the market based on source, application, end user.
Market Size & Forecast (2023-2030), By Source, USD Million
Human Source
Humanized Source
Chimeric Source
Others
Market Size & Forecast (2023-2030), By Application, USD Million
Oncology
Autoimmune Diseases
Infectious Diseases
Hematologic Diseases
Ophthalmology
Others
Market Size & Forecast (2023-2030), By End User, USD Million
Hospitals
Long-term Care Facilities
Others
Market Size & Forecast (2023-2030), By Region, USD Million
North America
US
Canada
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Rest of Asia Pacific
Latin America
Middle East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
[email protected]
Top comments (0)